Loading...
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Arzumanyan, Alla Blain, Stacy W. Holcombe, Randall F. Mahajna, Jamal Marino, Maria Martinez-Chantar, Maria L. Nawroth, Roman Sanchez-Garcia, Isidro
Arzumanyan, Alla
Blain, Stacy W.
Holcombe, Randall F.
Mahajna, Jamal
Marino, Maria
Martinez-Chantar, Maria L.
Nawroth, Roman
Sanchez-Garcia, Isidro
Citations
Altmetric:
Genre
Journal article
Date
2015-11-18
Advisor
Committee member
Group
Department
Biology
Permanent link to this record
Collections
Files
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1016/j.semcancer.2015.02.006
Abstract
Proliferation is an important part of cancer development and progression. This is manifest by altered expression and/or activity of cell cycle related proteins. Constitutive activation of many signal transduction pathways also stimulates cell growth. Early steps in tumor development are associated with a fibrogenic response and the development of a hypoxic environment which favors the survival and proliferation of cancer stem cells. Part of the survival strategy of cancer stem cells may manifested by alterations in cell metabolism. Once tumors appear, growth and metastasis may be supported by overproduction of appropriate hormones (in hormonally dependent cancers), by promoting angiogenesis, by undergoing epithelial to mesenchymal transition, by triggering autophagy, and by taking cues from surrounding stromal cells. A number of natural compounds (e.g., curcumin, resveratrol, indole-3-carbinol, brassinin, sulforaphane, epigallocatechin-3-gallate, genistein, ellagitannins, lycopene and quercetin) have been found to inhibit one or more pathways that contribute to proliferation (e.g., hypoxia inducible factor 1, nuclear factor kappa B, phosphoinositide 3 kinase/Akt, insulin-like growth factor receptor 1, Wnt, cell cycle associated proteins, as well as androgen and estrogen receptor signaling). These data, in combination with bioinformatics analyses, will be very important for identifying signaling pathways and molecular targets that may provide early diagnostic markers and/or critical targets for the development of new drugs or drug combinations that block tumor formation and progression.
Description
Citation
Citation to related work
Elsevier
Has part
Seminars in Cancer Biology, Vol. 35, Supplement
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu